KalVista Pharmaceuticals Stock (NASDAQ:KALV)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$10.61

52W Range

$7.21 - $16.88

50D Avg

$11.59

200D Avg

$12.41

Market Cap

$502.60M

Avg Vol (3M)

$337.17K

Beta

0.89

Div Yield

-

KALV Company Profile


KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

150

IPO Date

Apr 09, 2015

Website

KALV Performance


KALV Financial Summary


Apr 24Apr 23Apr 22
Revenue---
Operating Income$-140.44M$-110.87M$-96.61M
Net Income-$-74.85M$-68.51M
EBITDA$-140.44M$-110.24M$-94.51M
Basic EPS-$-2.68$-2.80
Diluted EPS-$-2.68$-2.80

Fiscal year ends in Apr 24 | Currency in USD

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
GOSSGossamer Bio, Inc.
CGEMCullinan Oncology, Inc.
DYNDyne Therapeutics, Inc.
VRDNViridian Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
IMCRImmunocore Holdings plc
COGTCogent Biosciences, Inc.
REPLReplimune Group, Inc.
SNDXSyndax Pharmaceuticals, Inc.
KRONKronos Bio, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
MRSNMersana Therapeutics, Inc.
CYTKCytokinetics, Incorporated
KURAKura Oncology, Inc.
KRTXKaruna Therapeutics, Inc.
LYRALyra Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.
MIRMMirum Pharmaceuticals, Inc.